San Antonio Breast Cancer Symposium 2007—Adjuvant Endocrine Therapy Update: ATAC 100 Highlights

Anil A. Joy

doi:10.3747/co.2008.203

You are currently viewing a new version of our website. To view the old version click .

Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..

Article

1 January 2008

San Antonio Breast Cancer Symposium 2007—Adjuvant Endocrine Therapy Update: ATAC 100 Highlights

Department of Oncology, University of Alberta, and Cross Cancer Institute, Edmonton, Alberta

Curr. Oncol.2008, 15(1), 68-69;https://doi.org/10.3747/co.2008.203

Version Notes

Order Reprints

Excerpt

Note: In lieu of an abstract, this is an excerpt from the first page.

The two main classes of adjuvant hormonal therapy used in the treatment of postmenopausal women with hormone receptor–positive breast cancer are selective estrogen receptor modulators (for example, tamoxifen) and the aromatase inhibitors (AIs—for example, anastrozole, letrozole, exemestane). [...]

Article Metrics

Citations

Article Access Statistics

Journal Statistics

Multiple requests from the same IP address are counted as one view.

Trastuzumab in the Adjuvant Setting: Concurrent or Sequential? It Takes Two to Tango!

The Role of DNA Hypermethylation and Demethylation in Cancer and Cancer Therapy